drugset
drugset / Trial / NCT02385240

Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea

NCT02385240 ↗

Phase 3 Completed 552 enrolled Padagis LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare safety and efficacy of Perrigo's rosacea drug product compared to an FDA approved rosacea drug product in the treatment of facial erythema of rosacea.

Timeline

Start
2015-03
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.33 % Topical

Indications

rosacea